A Phase 2, Open-Label, Randomized Two-part, Multiple Dose Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic Hepatitis B Virus

Trial Profile

A Phase 2, Open-Label, Randomized Two-part, Multiple Dose Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic Hepatitis B Virus

Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs SB 9200 (Primary) ; Tenofovir disoproxil fumarate
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Acronyms ACHIEVE
  • Sponsors Spring Bank Pharmaceuticals
  • Most Recent Events

    • 31 Jul 2017 According to a Spring Bank Pharmaceuticals media release, the company plans to report top-line results from the second monotherapy dosing cohort of this trial in 4Q 2017. Top-line results from the first cohort of patients in this trial have been disclosed and patient enrollment in the second cohort of this trial has been completed.
    • 22 May 2017 According to a Spring Bank Pharmaceuticals media release, the company's management team plans to host a conference call to discuss top-line results from the initial 25mg monotherapy dosing cohort of the Phase 2a segment of this trial.
    • 15 May 2017 The company expects top-line results from the 25mg monotherapy dosing cohort of this trial in the coming weeks, according to a Spring Bank Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top